Larazotide vs Ziconotide
Head-to-head comparison of Larazotide (Larazotide acetate (AT-1001)) and Ziconotide (ω-Conotoxin MVIIA (ziconotide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Larazotide | Ziconotide |
|---|---|---|
| Category | Gastrointestinal | Pain Management |
| Full Name | Larazotide acetate (AT-1001) | ω-Conotoxin MVIIA (ziconotide) |
| Molecular Weight | N/A | 2639.1 Da |
| Half-Life | short; designed for local gut action | approximately 4.5 hours |
| Amino Acids | 8 | 25 |
| Typical Dose | 0.5-4 mg TID (clinical studies) | 0.5-19.2 mcg/day |
| Route | Oral | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 500 |
| Research Status | Clinical | Approved |
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Research Overview
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.